… efficacy of gefitinib in patients with uncommon mutations, we conducted a post-hoc analysis
of the NEJ002, which compared gefitinib … advanced NSCLC with activating EGFR mutations. …

… -TKIs in NSCLC patients with common and rare EGFR mutations. To the best of our … the
efficacy of erlotinib, gefitinib, and afatinib in patients with rare and common EGFR mutations. …

… efficacy of gefitinib in brain metastases from NSCLC and evaluated the association of this
efficacy with EGFR mutations… association between the efficacy of gefitinib and EGFR mutations. …

… Therefore, this study has a bias against the effectiveness of gefitinib. Further prospective
or retrospective multicenter studies with large sample sizes are warranted. However, this …

… efficacy of gefitinib therapy does not differ according to the type of active EFGR mutation in
… trials are awaited to clarify the clinical value of analysis of EGFR mutations in these patients. …

… cell lung cancer (NSCLC) to gefitinib, an EGFR tyrosine kinase inhibitor. The objective of …
efficacy of gefitinib in patients with stage III/IV NSCLC whose tumors carried EGFR mutations…

… of afatinib for treating tumors with uncommon mutations was reported [17,18]. Our study
confirms the previous efficacy data of afatinib for NSCLC harboring uncommon EGFR mutations …

… -small cell lung cancer (NSCLC) to gefitinib, an EGFR tyrosine kinase inhibitor. The clinical
… the efficacy of gefitinib in patients with stageIII/IV NSCLC that had the EGFR mutations. …

… the efficacy of gefitinib and erlotinib in patients with pulmonary adenocarcinoma, whose
tumor EGFR mutation … Pulmonary adenocarcinoma patients who began receiving gefitinib or …

… the approach to detect the EGFR mutations in plasma or pleural effusion from 88 advanced
NSCLC patients and compared the relationship of EGFR mutations with gefitinib’s efficacy. …